BR0309134A - Moléculas de anticorpos anti-cea antiidiótipos e seu uso como vacina para câncer - Google Patents
Moléculas de anticorpos anti-cea antiidiótipos e seu uso como vacina para câncerInfo
- Publication number
- BR0309134A BR0309134A BR0309134-1A BR0309134A BR0309134A BR 0309134 A BR0309134 A BR 0309134A BR 0309134 A BR0309134 A BR 0309134A BR 0309134 A BR0309134 A BR 0309134A
- Authority
- BR
- Brazil
- Prior art keywords
- cea
- biotype
- molecules
- antibody
- antibody molecules
- Prior art date
Links
- 230000002494 anti-cea effect Effects 0.000 title abstract 2
- 238000009566 cancer vaccine Methods 0.000 title abstract 2
- 229940022399 cancer vaccine Drugs 0.000 title abstract 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108010009575 CD55 Antigens Proteins 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- 230000006023 anti-tumor response Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"MOLéCULAS DE ANTICORPOS ANTI-CEA ANTIIDIóTIPOS E SEU USO COMO VACINA PARA CâNCER". A presente invenção refere-se a moléculas, preferivelmente imunoglobulinas projetadas, adequadas para uso como uma vacina antiidiótipo para tumores positivos para CEA. As moléculas induzem uma resposta imune mediada tanto pela classe I do MHC quanto pela classe II do MHC às células de tumor contendo o CEA para uma resposta antitumor eficiente e uniforme em um hospedeiro. A presente invenção refere-se a versões modificadas de anticorpos anti-CEA antiidiótipos, preferivelmente o anticorpo de camundongo 708, com propriedades de vacinação aperfeiçoadas. As modificações estão relacionadas à introdução de tratos de seq³ência que se derivam de, por exemplo, CEA, antígeno CD55 e epitopos do MHC específicos para câncer de CEA, nas regiões variáveis das ditas moléculas de anticorpos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02007885 | 2002-04-09 | ||
| PCT/EP2003/003580 WO2003084996A2 (en) | 2002-04-09 | 2003-04-07 | Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0309134A true BR0309134A (pt) | 2005-02-01 |
Family
ID=28685846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0309134-1A BR0309134A (pt) | 2002-04-09 | 2003-04-07 | Moléculas de anticorpos anti-cea antiidiótipos e seu uso como vacina para câncer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050222392A1 (pt) |
| EP (1) | EP1492819A2 (pt) |
| JP (1) | JP2005535571A (pt) |
| KR (1) | KR20040101428A (pt) |
| CN (1) | CN1646567A (pt) |
| AU (1) | AU2003229614A1 (pt) |
| BR (1) | BR0309134A (pt) |
| CA (1) | CA2481829A1 (pt) |
| MX (1) | MXPA04009771A (pt) |
| PL (1) | PL371202A1 (pt) |
| RU (1) | RU2004133040A (pt) |
| WO (1) | WO2003084996A2 (pt) |
| ZA (1) | ZA200409034B (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4790413B2 (ja) * | 2002-10-08 | 2011-10-12 | イミューノメディクス、インコーポレイテッド | 抗体療法 |
| CN100425290C (zh) * | 2003-10-30 | 2008-10-15 | 中山大学中山医学院科技开发中心 | 人cea基因疫苗、其构建方法及其在制备防治肿瘤疫苗中的应用 |
| TWI434855B (zh) * | 2006-11-21 | 2014-04-21 | Hoffmann La Roche | 結合物及其在免疫分析中作為參考標準之用途 |
| WO2008138139A1 (en) * | 2007-05-14 | 2008-11-20 | Vancouver Biotech Ltd. | Carbohydrate-containing pan cancer marker |
| GB2451928B (en) * | 2007-06-21 | 2011-03-16 | Angelica Therapeutics Inc | Modified Toxins |
| WO2009110944A1 (en) * | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
| CN102838676A (zh) * | 2012-09-26 | 2012-12-26 | 李彬 | 一种癌胚抗原单抗及包含该抗体的芯片以及应用 |
| JP2016519651A (ja) | 2013-03-15 | 2016-07-07 | アンジェリカ セラピューティックス，インク． | 改質された毒素 |
| CN112557662B (zh) * | 2021-02-22 | 2021-07-06 | 和卓生物科技（上海）有限公司 | 一种结直肠癌检测试剂盒 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997032021A1 (en) * | 1996-02-28 | 1997-09-04 | Cancer Research Campaign Technology Limited | Therapeutic agents based on monoclonal anti-idiotypic antibody 105ad7 |
| DE69734109T2 (de) * | 1996-03-20 | 2006-06-29 | Immunomedics, Inc. | Humanisierung von anti-carcinoembryonalen Antigen anti-idiotypischen Antikörper und dessen Verwendung als Tumorvakzin und zur Markierung |
| GB2339430A (en) * | 1997-05-21 | 2000-01-26 | Biovation Ltd | Method for the production of non-immunogenic proteins |
| GB0102145D0 (en) * | 2001-01-26 | 2001-03-14 | Scancell Ltd | Substances |
-
2003
- 2003-04-07 EP EP03722406A patent/EP1492819A2/en not_active Withdrawn
- 2003-04-07 JP JP2003582190A patent/JP2005535571A/ja active Pending
- 2003-04-07 US US10/510,523 patent/US20050222392A1/en not_active Abandoned
- 2003-04-07 BR BR0309134-1A patent/BR0309134A/pt not_active Application Discontinuation
- 2003-04-07 MX MXPA04009771A patent/MXPA04009771A/es not_active Application Discontinuation
- 2003-04-07 AU AU2003229614A patent/AU2003229614A1/en not_active Abandoned
- 2003-04-07 CA CA002481829A patent/CA2481829A1/en not_active Abandoned
- 2003-04-07 KR KR10-2004-7016156A patent/KR20040101428A/ko not_active Application Discontinuation
- 2003-04-07 WO PCT/EP2003/003580 patent/WO2003084996A2/en not_active Application Discontinuation
- 2003-04-07 PL PL03371202A patent/PL371202A1/xx unknown
- 2003-04-07 RU RU2004133040/13A patent/RU2004133040A/ru not_active Application Discontinuation
- 2003-04-07 CN CNA038078643A patent/CN1646567A/zh active Pending
-
2004
- 2004-11-08 ZA ZA200409034A patent/ZA200409034B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005535571A (ja) | 2005-11-24 |
| AU2003229614A1 (en) | 2003-10-20 |
| CN1646567A (zh) | 2005-07-27 |
| WO2003084996A2 (en) | 2003-10-16 |
| CA2481829A1 (en) | 2003-10-16 |
| ZA200409034B (en) | 2005-10-20 |
| KR20040101428A (ko) | 2004-12-02 |
| MXPA04009771A (es) | 2004-12-13 |
| WO2003084996A3 (en) | 2004-02-05 |
| PL371202A1 (en) | 2005-06-13 |
| US20050222392A1 (en) | 2005-10-06 |
| EP1492819A2 (en) | 2005-01-05 |
| RU2004133040A (ru) | 2005-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Buonaguro et al. | Selecting target antigens for cancer vaccine development | |
| Marshall et al. | Phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM alone and sequentially with vaccinia-CEA (6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen–expressing carcinomas | |
| Rosenberg | Progress in human tumour immunology and immunotherapy | |
| Peoples et al. | Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients | |
| Holmes et al. | Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine | |
| Chudley et al. | DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time | |
| CY1114855T1 (el) | Αντισωματα και μορια που προερχονται απο αυτα που δεσμευονται στις πρωτεϊνες toy steap-1 | |
| Barve et al. | Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non–small-cell lung cancer | |
| Sears et al. | AE37: a novel T-cell-eliciting vaccine for breast cancer | |
| Sato et al. | A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients | |
| Wang et al. | Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens | |
| Sawada et al. | A glypican-3-derived peptide vaccine against hepatocellular carcinoma | |
| BR0309134A (pt) | Moléculas de anticorpos anti-cea antiidiótipos e seu uso como vacina para câncer | |
| Nuber et al. | Fine analysis of spontaneous MAGE-C1/CT7–specific immunity in melanoma patients | |
| Plate | Clinical trials of vaccines for immunotherapy in pancreatic cancer | |
| Saha et al. | Curing glioblastoma: oncolytic HSV-IL12 and checkpoint blockade | |
| Kida et al. | Immune responses against tumour‐associated antigen‐derived cytotoxic T lymphocyte epitopes in cholangiocarcinoma patients | |
| Vieweg et al. | Technology insight: vaccine therapy for prostate cancer | |
| Hashemzadeh et al. | Novel predicted B-cell epitopes of PSMA for development of prostate cancer vaccine | |
| Buonaguro et al. | Cancer vaccines for hepatocellular carcinoma: future directions | |
| Duperret et al. | Designing consensus immunogens to break tolerance to self-antigens for cancer therapy | |
| Kang et al. | Control of spontaneous ovarian tumors by CD8+ T cells through NKG2D-targeted delivery of antigenic peptide | |
| BRPI0409321A (pt) | antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo | |
| Loibner et al. | A randomized placebo-controlled phase II study with the cancer vaccine IGN101 in patients with epithelial solid organ tumors (IGN101/2–01) | |
| Albuquerque | Unnatural glycopeptides and proteins and their use in antigen detection and immunization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |